& Events
& Events
News
& Events
Sep 5, 2022 Inversago Pharma presents data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
MONTREAL (CANADA) – September 5, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), currently held in Barcelona, Spain and online. These data show that Inversago’s INV-101 (zevaquenabant), a […]
Aug 18, 2022 Inversago Pharma to present preclinical data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
MONTREAL (CANADA) – August 18, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online. Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, […]
Jun 9, 2022 Inversago Pharma to participate to BIO International Convention 2022 in San Diego, CA
MONTREAL (CANADA) – June 09, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. – François Ravenelle, PhD, Chief Executive Officer […]
May 19, 2022 Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
MONTREAL (CANADA) – May 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show […]